The study Progress in large-scale purification of Factor VIII/von Willebrand factor concentrates using ion-exchange chromatographyhas been published on “Vox Sanguinis” (2008) 95, 298–307,
Entirely conducted by Kedrion’s researchers, the study presents the results of the development of a new purification method for a Factor VIII/von Willebrand Factor concentrate. A process scale-up is now being investigated for industrial feasibility.
The authors of the study are Filippo Mori, Ilaria Nardini, Paola Rossi, Claudio Farina (basic research manager) and Claudia Nardini (industrial research and development manager).
The trial described in the article helped develop a new purification process for Factor VIII/von Willebrand factor with a high yield and purity. Once the chromatographic parameters are optimised, the selected resin (Fractogel EMD TMAE) can process twice as much product as the ordinary production process, which will also save on processing time. The new purification process can be used to adjust the vWF content in the end product, so the result will be one or more very pure and stable drugs specifically designed to treat Haemophilia A or Von Willebrand disease
Progress in large-scale purification of Factor VIII/von Willebrand factor concentrates using ion-exchange chromatography.
